Phaseline

Companies › Moonlight Bio

Moonlight Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ML261
DLL3-directed autologous CAR-T cell therapy
–Phase 1Small Cell Lung Cancer (SCLC )Mar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07488923ML261Phase 1Small Cell Lung Cancer (SCLC )OncologyMar 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.